Normophthal
An oral capsule preparation sold in the Khavinson product line for eye health. It is the emptiest entry in this codex, and that emptiness is the finding: not one PubMed record anywhere mentions the name in a title or abstract, in any language. The only places the word appears in reference data are two chemical-name indexes, both of which file it as a synonym of the Lys-Glu dipeptide Vilon. The product's own label calls its content a peptide complex and names no sequence. This entry prints none either.
This is a peptide complex. It contains many peptides and has no single sequence — printing one would be fabrication.
Bioregulator context
Target tissue: retina and ocular tissue (ophthalmic)
That a peptide preparation directed at eye tissue corrects age-related and dystrophic changes in the retina by restoring protein synthesis inside retinal cells. The claim is made on vendor and manufacturer material; no published study making it was found.
The manufacturer's material describes correction of a peptide deficiency and restoration of intracellular protein synthesis in retinal cells. No experimental work supporting this for this preparation was located, and no mechanism is described in any indexed paper.
Mechanism
Claimed
Normalises retinal function, corrects dystrophic and inflammatory retinal change, supports glaucoma therapy and speeds recovery after eye surgery.
Actually established
Nothing. No study of this preparation exists in the indexed literature, so there is no established mechanism, no established effect, and nothing to describe beyond what the label asserts.
How good is the evidence
There is no evidence. A PubMed search for the name on 2026-08-06 returned no records containing it in title or abstract; the unfiltered search returns 57 results only because NCBI silently rewrites the query to 'lysylglutamic acid', the MeSH concept that carries Normophthal as one of its entry terms. That rewrite is itself the most informative fact available: NLM's index does not treat this as a substance at all, but as another name for Lys-Glu. Everything else on this page comes from vendor and manufacturer product pages, which are an acceptable source for what is being marketed and for nothing else.
Not applicable — there are no studies to concentrate. The two product pages read for this entry describe the same manufacturer's product and give slightly different excipient lists, which is the only cross-source comparison this entry supports.
Claims, one at a time
Each claim carries its own evidence tier. A compound is never simply "well studied" — some of its claims may be, others not at all.
| Claim | Verdict | Evidence | Basis |
|---|---|---|---|
| Normophthal is the Lys-Glu dipeptide | contradicted | Anecdote | Two chemical-name indexes say so and the product label does not. PubChem CID 7010502, whose synonym list includes 'Vilon', 'AB-0 peptide' and 'Normophthal', and NLM's MeSH supplementary concept 'lysylglutamic acid', whose entry terms include both 'Vilon' and 'normophthal', both file the trade name against the dipeptide — which is why the codex resolver returned KE for this name with a clean composition-gate match. But the manufacturer's own label declares 'peptide complex AKS-G (lysine, glutamic acid)', a mixture with no stated sequence, quantity or purity, and sells it as an oral capsule rather than as the dipeptide. The two accounts cannot both be right, and no source resolves them. The codex therefore prints no sequence and no CID: the CID belongs to Vilon, which has its own entry, and claiming it here would assert an identity nobody has demonstrated. |
| Normalises retinal function and corrects degenerative eye disease including maculopathy and retinopathy | untested | Anecdote | This is the product's central marketing claim, taken from two vendor pages read on 2026-08-06. No study of this preparation for any eye condition exists in the PubMed-indexed literature — not a trial, not a case series, not a case report. The claim is recorded here so that it can be answered rather than left unaddressed, and 'untested' is the literal and complete state of the evidence. |
| Well tolerated with no side effects or allergic reactions | unsupported | Anecdote | One vendor page states this outright. No safety study, adverse-event registry or post-marketing report for this preparation was found. A safety claim with no data behind it is not a weak claim, it is an unmade measurement — and 'no side effects' is a stronger assertion than any trial in this whole codex is powered to support, including the ones that exist. |
- No study of this preparation exists. A PubMed search on 2026-08-06 returned zero records containing the name in title, abstract or text — there is no trial, no animal work, no cell work and no case report.
- PubMed does not treat the name as a substance. The unfiltered query is silently rewritten to 'lysylglutamic acid', so a searcher who does not read the query translation will believe they have found 57 papers about Normophthal when none of them mentions it.
- It is not established whether the product contains a defined dipeptide, a mixture of peptides, or something else. Two chemical indexes say Lys-Glu; the label says 'peptide complex AKS-G'; neither is checkable against the other.
- The label states no quantity of peptide per capsule, so even if the identity were known, the amount would not be.
- What 'AKS-G' designates is not established by any source read here.
- No pharmacokinetic data exists, and for an oral peptide preparation the central question — whether anything survives digestion and reaches ocular tissue — has not been examined for this product or, as far as this entry can establish, for any product in this line.
- This entry is built entirely from two chemical-database records and two vendor product pages. No primary source about this preparation was read, because none was found to exist.